Síguenos en Twitter     Síguenos en Facebook     Síguenos en Google+     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Yahoo Mail     Dropbox     Instagram     Pinterest     Slack     Google Drive     Reddit     StumbleUpon     Print

SOBRE EL AUTOR **

Mi foto
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com

WORLD EMERGENCY MEDICINE SOCIETIES

My Heart is Racing! Select Cardiac Arrhythmias and Practice Updates

Buscar en contenido

Contenido:

sábado, 21 de abril de 2012

Nuevos anticoagulantes

ESC issues position paper on new anticoagulants
Chieti, Italy - In a "position paper" on the new oral anticoagulants, a group of experts from the European Society of Cardiology Working Group on Thrombosis are enthusiastic about the new agents in AF, but not so impressed with their use in ACS (1)
*
To heartwire, lead author of the position paper, Dr Raffaele De Caterina (G d'Annunzio University, Chieti, Italy), commented: "We are comparing data from different trials, so these are indirect comparisons, and therefore it is difficult to reach any firm conclusions. But if I had to rank the results of the three major trials in AF, I would put ARISTOTLE with apixaban at the top, with RE-LY (dabigatran) second and ROCKET (rivaroxaban) third."
(1) De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes. ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012; 59:1413-25